GLP-1s (glucagon-like peptide-1 receptor agonists) are FDA-approved medications used for long-term weight management
They cannot claim to treat, cure, or prevent diseases, but they can make "structure/function" claims like "supports metabolism" or "promotes healthy appetite." These vague claims allow products like Peaka GLP-1 to imply pharmaceutical-level benefits without providing pharmaceutical-level evidence
Weeks 9 to 16: Progressive Dose Escalation (1.0mg to 1.7mg) By the time most patients reach the 1.0mg dose, they have generally developed a good understanding of their personal side effect triggers and have adopted dietary strategies that minimise discomfort
While we are bound by the pricing structures of our pharmacy and drug manufacturers, were thrilled to announce the launch of our very first TAC Grant
For bipolar disorder, estimates varied across studies (Hou L: OR = 0.90, 95% CI [0.880.93]
Novo Nordisk has nominated semaglutide for inclusion in the FDAs Demonstrable Difficulties for Compounding Lists